This trial is evaluating whether Metformin DR will improve 1 primary outcome and 3 secondary outcomes in patients with Diabetes Mellitus, Type 2. Measurement will happen over the course of Baseline to 28 weeks.
This trial requires 675 total participants across 3 different treatment groups
This trial involves 3 different treatments. Metformin DR is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 3 and have had some early promising results.
"Metformin, in combination with other drugs, is typically used to treat patients with T2DM. The use of metformin, in combination with other drugs, is commonly prescribed." - Anonymous Online Contributor
"The signs of diabetes mellitus, type 2 include high blood sugar, feeling tired/mood swings, increased urination, pale complexion, frequent urination, decreased weight and increased thirst." - Anonymous Online Contributor
"Diabetes mellitus, type 2 is characterized by increased risk for cardiovascular events and peripheral neuropathy. These complications are associated with a high level of proinflammatory mediators and activation of the endothelium. Current data indicate that activation of circulating endothelial progenitor cells (EPCs) by [type 2 diabetes](https://www.withpower.com/clinical-trials/type-2-diabetes) is a major culprit in triggering high level of C-reactive protein (CRP). CRP is a surrogate marker for the inflammatory activity of endothelial cells and predicts cardiovascular events as well as nephropathy. Thus, targeting CRP level may be beneficial for preventing diabetic cardiovascular complications. In the present study we show for the first time that EPCs express functional receptors for CRP." - Anonymous Online Contributor
"Diabetes is common in the United States. The American Diabetes Association reported an estimated 114 million U.S. citizens had diabetes in 2007. In 2007, an estimated 45% of the population had diabetes. The average age for onset of diabetes and related health problems was 40.9 years. In 2007, the estimated average medical cost for diabetes in the United States in 2007 was $10,835 per person per year. Diabetes affects more affluent Americans than those in poverty." - Anonymous Online Contributor
"Type 2 diabetes can occur due to a number of factors which affect insulin sensitivity. It causes the most micro- and macro-vascular complications of diabetes and is the largest and most costly cause of non-insulin-dependent diabetes. Diabetes type 2 should therefore be managed to prevent these complications." - Anonymous Online Contributor
"Diabetes has a substantial impact on patient lives, causes significant financial losses and has proven to be self-sustaining. Patients with diabetes are generally managed by a multidisciplinary team with specialist nurses, dietitians, podiatrists and optometrists playing a role. The overall aim of the multidisciplinary team is to ensure that all patients have adequate and appropriate foot care. This is the first step in the prevention and management of diabetes-related foot disease. There are two main types of foot care: prevention and treatment. Prevention refers to the control of risk factors for diabetic foot disease by lowering blood pressure, control blood sugar, regular check-ups and footwear." - Anonymous Online Contributor
"Diabetes-type 2 is a chronic non-life threatening disease that can be effectively treated with lifestyle modification, and, when well managed, can improve overall health and quality of life. Lifestyle adjustments in terms of diet, physical activity and appropriate management of oral antihypertensive medication can improve insulin sensitivity, glycaemic control and reduce the risk of cardiovascular morbidities." - Anonymous Online Contributor
"In a recent study, findings suggest that the use of metformin for a median of 6 years resulted in the greatest improvement in quality of life. In a recent study, findings of this study reinforce the emerging consensus, in the medical literature, that clinicians should advise patients with DM, type 2 about the potential role of metformin on QOL." - Anonymous Online Contributor
"No statistically significant difference between patients treated with metformin and those not treated was demonstrated. Additional studies are required to see whether metformin would be as efficacious when used in the adjunctive treatment of diabetic patients treated with glucocorticoid or immunosuppressive agents." - Anonymous Online Contributor
"Individuals with well-controlled type 2 diabetes are at a high risk for atherosclerotic cardiovascular disease, and clinical trial design should take these factors into account." - Anonymous Online Contributor
"In the United States, individuals with diabetes mellitus, type 2, and overweight constitute the majority of individuals diagnosed with the disease. To avoid developing diabetes mellitus type 2, obesity, which is directly linked to diet choices and exercise, must be avoided." - Anonymous Online Contributor
"The use of metformin is often limited by adverse side effects, particularly diarrhoea, nausea and/or vomiting. Although newer formulations of metformin may overcome these adverse effects, the development of metformin to achieve therapeutic plasma concentration will still require improvement in the oral bioavailability of metformin to be clinically effective in type 2 diabetes mellitus." - Anonymous Online Contributor